MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 03-09-2026
Anixa Biosciences Operating Income 2011-2026 | ANIX
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Anixa Biosciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -11.7 M | -13.8 M | -11 M | -13.9 M | -13.1 M | -9.98 M | -11.9 M | -14.3 M | -6.08 M | -4.51 M | -945 K | -5.04 M | -7.92 M | -4.13 M | -5.03 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -945 K | -14.3 M | -8.89 M |
Quarterly Operating Income Anixa Biosciences
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -2.72 M | - | -2.44 M | -3 M | -3.39 M | - | -3.59 M | -3.47 M | -3.61 M | - | -2.84 M | -2.56 M | -2.56 M | -10.3 M | -2.8 M | -3.59 M | -2.23 M | -9.06 M | -4.39 M | -2.44 M | -2.63 M | -7.74 M | -2.44 M | -2.67 M | -4.98 M | -9.76 M | -2.18 M | -2.59 M | -1.87 M | -8.88 M | -5.61 M | -1.4 M | -1.39 M | -4.34 M | -1.73 M | -1.21 M | -1.47 M | -3.6 M | -975 K | -1.15 M | 3.86 M | 233 K | -1.49 M | -2.13 M | -1.96 M | -3.48 M | -160 K | -1.36 M | -2.07 M | -6.14 M | -2.22 M | -1.85 M | -887 K | -2.41 M | -643 K | -878 K | -1.53 M | -4.02 M | -1.21 M | -1.29 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.86 M | -10.3 M | -2.9 M |
Operating Income of other stocks in the Diagnostics research industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
-46 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
CareDx, Inc
CDNA
|
-30.8 M | $ 21.13 | 1.51 % | $ 1.13 B |  USA |
 |
Accelerate Diagnostics
AXDX
|
-14 M | - | -61.36 % | $ 2.46 M | USA |
 |
Agilent Technologies
A
|
1.35 B | $ 115.13 | -0.36 % | $ 35 B | USA |
 |
Co-Diagnostics
CODX
|
-50.2 M | $ 1.53 | -1.29 % | $ 2.04 M | USA |
 |
Castle Biosciences
CSTL
|
8.67 M | $ 24.66 | 0.69 % | $ 685 M | USA |
|
Akumin
AKU
|
-28.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Biocept
BIOC
|
-32 M | - | -13.05 % | $ 7.29 M | USA |
 |
Fulgent Genetics
FLGT
|
-73.9 M | $ 14.29 | -5.92 % | $ 432 M | USA |
 |
Aspira Women's Health
AWH
|
-7.91 M | - | -6.19 % | $ 10.5 M | USA |
 |
ICON Public Limited Company
ICLR
|
1.1 B | $ 115.11 | -2.73 % | $ 9.49 B |  Irlanda |
 |
Chembio Diagnostics
CEMI
|
-23.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
-25.9 M | - | - | $ 9.42 M |  Israel |
 |
Lantheus Holdings
LNTH
|
311 M | $ 85.08 | 0.54 % | $ 5.74 B | USA |
 |
Heska Corporation
HSKA
|
-20.3 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-20.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
Medpace Holdings
MEDP
|
535 M | $ 415.89 | -0.66 % | $ 12 B | USA |
 |
Illumina
ILMN
|
-833 M | $ 131.26 | 3.57 % | $ 20.9 B | USA |
 |
NeoGenomics
NEO
|
-116 M | $ 9.44 | 1.94 % | $ 1.21 B | USA |
 |
National Research Corporation
NRC
|
22.6 M | $ 17.17 | 4.31 % | $ 384 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
553 M | $ 26.5 | 0.61 % | $ 20 B |  Niderland |
 |
DermTech
DMTK
|
-104 M | - | -11.32 % | $ 2.94 M | USA |
 |
Personalis
PSNL
|
-68.3 M | $ 5.53 | 0.18 % | $ 328 M | USA |
 |
Global Cord Blood Corporation
CO
|
609 M | - | - | $ 399 M |  China |
 |
Genetron Holdings Limited
GTH
|
-518 M | - | 0.12 % | $ 80.1 M | China |
 |
Senseonics Holdings
SENS
|
-68.3 M | $ 5.13 | -22.39 % | $ 214 M | USA |
 |
Charles River Laboratories International
CRL
|
25.2 M | $ 164.81 | -1.29 % | $ 8.17 B | USA |
 |
Enzo Biochem
ENZ
|
-12.4 M | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
-206 M | - | - | $ 19.8 B | USA |
 |
Guardant Health
GH
|
-437 M | $ 87.91 | 0.95 % | $ 11 B | USA |
 |
Thermo Fisher Scientific
TMO
|
7.75 B | $ 473.92 | -1.05 % | $ 179 B | USA |
 |
Motus GI Holdings
MOTS
|
-11.9 M | - | -34.28 % | $ 263 K | Israel |
 |
Twist Bioscience Corporation
TWST
|
-136 M | $ 59.17 | 1.23 % | $ 3.54 B | USA |
 |
Myriad Genetics
MYGN
|
-387 M | $ 4.91 | 3.37 % | $ 455 M | USA |
 |
Interpace Biosciences
IDXG
|
4.08 M | $ 1.98 | -0.5 % | $ 8.76 M | USA |
 |
Waters Corporation
WAT
|
271 M | $ 307.99 | -0.4 % | $ 18.3 B | USA |
 |
Soleno Therapeutics
SLNO
|
9.41 M | $ 52.86 | 0.08 % | $ 2.69 B | USA |
 |
QIAGEN N.V.
QGEN
|
466 M | - | - | $ 10.6 B | Niderland |
 |
Biomerica
BMRA
|
-5.14 M | $ 2.18 | - | $ 5.01 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
1.38 B | $ 257.15 | 0.14 % | $ 21.4 B | USA |
 |
Celcuity
CELC
|
-172 M | $ 119.5 | -1.52 % | $ 5.59 B | USA |
 |
Natera
NTRA
|
-541 M | $ 204.73 | -0.7 % | $ 20.1 B | USA |
 |
Neogen Corporation
NEOG
|
-1.06 B | $ 9.53 | 1.33 % | $ 2.07 B | USA |
 |
Invitae Corporation
NVTA
|
-94.9 M | - | - | $ 21.2 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
1.56 B | $ 194.33 | 0.07 % | $ 21.6 B | USA |
 |
OpGen
OPGN
|
325 K | - | -16.95 % | $ 1.54 M | USA |